William Conkling
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.
Transaction History
| IDT | ▲ Buy | Grant | 673 | $38K | 6/9/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 6,008 | $26K | 6/2/2026 | View on chart |
| TARA | ▲ Buy | Grant | 26,000 | $0 | 1/16/2026 | View on chart |
| TARA | ▲ Buy | Grant | 50,000 | $0 | 6/2/2025 | View on chart |
| RFL | ▲ Buy | Grant | 27,454 | — | 3/25/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 14,814 | $29K | 3/21/2025 | View on chart |
| RFL | ▲ Buy | Grant | 60,000 | $117K | 1/13/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 12,807 | $24K | 12/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 3,431 | $6K | 10/25/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 12,696 | $22K | 9/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 13,295 | $19K | 6/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 15,473 | $26K | 3/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 13,602 | $25K | 12/21/2023 | View on chart |
| RFL | ▲ Buy | Grant | 40,000 | $61K | 10/25/2023 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 13,669 | $30K | 9/21/2023 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 15,170 | $33K | 6/21/2023 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 15,625 | $26K | 3/21/2023 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 56,149 | $99K | 12/21/2022 | View on chart |
| RFL | ▲ Buy | Grant | 623,732 | $0 | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
IDT Earnings and ESOP Registration Shape Investment Narrative
Recent reports highlight how strong earnings and ESOP share registration are altering the investment story for IDT. While one article flags potential risks in the telecom sector for the fourth quarter, the focus remains on the company's recent financial performance. The stock is currently trading near its 52-week high, reflecting these developments.
IDT Earnings and ESOP Registration Shape Investment Narrative. Recent reports highlight how strong earnings and ESOP share registration are altering the investment story for IDT. While one article flags potential risks in the telecom sector for the fourth quarter, the focus remains on the company's recent financial performance. The stock is currently trading near its 52-week high, reflecting these developments.